Is cancer incidence modified by SGLT2 inhibitors?
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induce...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN RU |
| Publié: |
Endocrinology Research Centre
2019
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e2a9284c7a5f48c585b794a470d53010 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|